

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addease COMMISSIONER FOR PATENTS PO Box 1430 Alexandria, Virginia 22313-1450 www.webjo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/777,552	02/12/2004	Daniel A. Hammer	UPN-4290 / P3164	6019
23377 7590 06/19/2009 WOODCOCK WASHBURN LLP			EXAM	IINER
CIRA CENTR	CIRA CENTRE, 12TH FLOOR SCHLIENTZ, LEAH H			Z, LEAH H
2929 ARCH S PHILADELPI	TREET IIA, PA 19104-2891		ART UNIT	PAPER NUMBER
			1618	
			MAIL DATE	DELIVERY MODE
			06/19/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Ī	Application No.	Applicant(s)				
	10/777,552	HAMMER ET AL.				
	Examiner	Art Unit				
	Leah Schlientz	1618				

The MAILING DATE of this communication appears on the cover sheet with the correspondence address
THE REPLY FILED 04 June 2009 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.
1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandomment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:
a) The period for reply expires months from the mailing date of the final rejection.
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In
no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL.
2. The Notice of Appeal was filed on A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of
filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). AMENDMENTS
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because
(a) ☐ They raise new issues that would require further consideration and/or search (see NOTE below);
(b) ☐ They raise the issue of new matter (see NOTE below);
(c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
(d) ☐ They present additional claims without canceling a corresponding number of finally rejected claims.
NOTE: (See 37 CFR 1.116 and 41.33(a)).
4. 📙 The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).
5. Applicant's reply has overcome the following rejection(s): 112 rejection.
Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
7. If or purposes of appeal, the proposed amendment(s) a) into the entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows:
Claim(s) allowed: Claim(s) objected to:
Claim(s) rejected:
Claim(s) withdrawn from consideration:
AFFIDAVIT OR OTHER EVIDENCE
8. The affidavit or other evidence field after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).
9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will <u>not</u> be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a
showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).
10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER
11. \(\)\ The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See continuation sheet.
12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s).
13. Other:
/Michael G. Hartley/ Supervisory Patent Examiner, Art Unit 1618

U.S. Patent and Trademark Office PTOL-303 (Rev. 08-06)

Continuation of 11

Claims 1, 10, 12, 13, 15-23, 32-42, 46, 52, 55, 60, 63, 65, 70-75, 78, 79, and 88-101 are rejected under 35 U.S.C. § 103(a) as being unpatentable over U.S. Patent No. 6, 159, 445 ("the Klaveness patent") and U.S. Patent No. 6, 179, 445 ("the Ungen patent") in U.S. Patent No. 6, 179, 429 ("the Ungen patent") in View of Lee, et al., Biotechnol. And Bioeng., 2001, 73, 135-145 ("the Lee article") and further in view of the Chem. Eur. J. 1995, 1,645-651 ("the Lin article"), for reasons set forth in the previous Office Action.

In response to applicant's argument that the examiner's conclusion of obviousness is based upon improper hindsight reasoning, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the applicant's disclosure, such a reconstruction is proper. See In re McLaughlin, 443 F.2d 1392, 170 USPO 299 (CCPA 1971).

In response to applicant's argument that there is no suggestion to combine the references, the examiner recognizes that obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching. suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. In the instant case, the Klaveness patent teaches optical probes including a variety of suitable vesicles including amphiphilic polymers, and that a variety of emissive agents are suitable including porphyrin. The Lee article teaches enhanced properties of certain polymeric vesicles, such as those claimed in instant claim 42. With regard to the specific identity of the porphyrin mojety used. Lin teaches linked perphryins and that they may be used in optical probes. One of ordinary skill could have readily substituted one perphryin moiety used in optical probes for another, and the result would have been predictable, that is preparation of an optical probe having an amphiphilic polymeric vesicle and emissive porphyrin incorporated therein for use in optical imaging. Applicant argues that nothing in Lin suggests that the compositions would be an improvement, and that without teaching of special properties of the particular porphyrins, sufficient motivation to make combination of art proposed by the Office is lacking. This is not found to be persausive. The Supreme Court in KSR International Co. v. Teleflex Inc., 550 U.S. , 82 USPQ2d 1385, 1395-97 (2007) identified a number of rationales to support a conclusion of obviousness which are consistent with the proper "functional approach" to the determination of obviousness as laid down in Graham. One such rationale includes the simple substitution of one known element for another to obtain predictable results. The key to supporting any rejection under 35 U.S.C. 103 is the clear articulation of the reason(s) why the claimed invention would have been obvious. See MPEP 2143. In the instant case, the substituted components (porphyrin and linked porphyrins) and their functions were known in the art at the time of the instant invention. For example, Lin teaches that linked porphryrins including an unsaturated hydrocarbon bridge may be used in optical probes. One of ordinary skill in the art could have substituted one known emissive agent in an optical probe for another, and the results of the substitution would have been predictable.